Navigation Links
Premier Research Announces Completion of Management Buyout
Date:6/10/2008

LONDON, June 10 /PRNewswire/ -- Premier Research Group plc, the international pharmaceutical services company, announces the completion of its previously announced management buyout. As a result, the company is no longer listed on the AIM market of the London Stock Exchange. The UK-based private equity firm ECI Partners provided funding for the transaction.

Said Dr. Simon Yaxley, Chief Executive Officer of Premier Research Group, "This event ensures that we are able to continue our thoughtful and measured 'buy-and-build' strategy to allow us to continue to deliver exceptional quality and service to our clients around the world." Dr. Yaxley continued, "Further, we are pleased to announce that our existing management team remains fully intact, and is as dedicated as ever to ensuring our clients' expectations are met or exceeded. As a result, our clients, both existing and prospective, will not experience any visible change in working with the Premier Research team."

Mr. Richard Chapman of ECI Partners commented, "We are extremely pleased to have concluded this important transaction. We have long been interested in the CRO sector, and are excited to have found a successful and growing company such as Premier Research in which to invest. Our comprehensive due diligence confirmed our belief that Premier Research is a company of the highest quality with an exceptional future in providing clinical research services to global pharmaceutical, biotechnology, and medical device companies. We are also pleased that the existing management team remains committed to the long-term success of the business."

About Premier Research

Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research.

Premier Research has 30 offices and operates in more than 30 countries across Europe and North America. Premier Research employs more than 1,200 clinical professionals dedicated first and foremost to fulfilling each client's requirements in a timely, accurate and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at our well-established network of dedicated clinical sites.


'/>"/>
SOURCE Premier Research Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety
2. Premier Research Group plc and Octagon Research Solutions, Inc. Announce Strategic Partnership
3. Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons
4. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
5. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
6. Premier Research Appoints Global Head of Human Resources
7. Premier Research Appoints Melissa Jones as Vice President, International Business Development
8. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
9. Texas Oncology-Baylor Sammons Cancer Center Recognized for Highest Commitment to Clinical Research at ASCO
10. Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
(Date:2/3/2016)... 3, 2016   ViaCyte, Inc ., a ... pluripotent stem cell-derived islet replacement therapy for the ... today announced that ViaCyte and Janssen Biotech, Inc., ... & Johnson, have agreed to consolidate the assets ... agreement provides ViaCyte with an exclusive license to ...
(Date:2/3/2016)... NEW YORK and HOLLISTON, Mass., Feb. 3, ... (Nasdaq: HART ), a biotechnology company developing ... esophagus, trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on ... in New York City . ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... Linux and Unix visualization solutions today announced the addition of a powerful “Session ... users to see the current state of the remote Linux desktop or other ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
Breaking Biology News(10 mins):